StockData
BioVie Inc. logo

BioVie Inc. (BIVI) stock

BIVINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as BIVIW
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$1.00−0.08 (-7.84%)

Close on Nov 17, 2026Market cap $7.51MP/E –Yield –

BioVie r&d expenses

Research and development expenses are spending on new products and technology.

BioVie's R&D Expenses for the twelve months ending Jun 30, 2026 was $13.96M, up 50.7% year over year. For fiscal 2026 it was $13.96M, up 50.7% from the year before. Over ten years it grew 80.6% a year on average. The highest annual figure on record is $33.30M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$13.96M+50.7%
FY2025Jun 30, 2025$9.27M-59.9%
FY2024Jun 30, 2024$23.10M-30.6%
FY2023Jun 30, 2023$33.30M+92.9%
FY2022Jun 30, 2022$17.26M+578.2%
FY2021Jun 30, 2021$2.54M+121.2%
FY2020Jun 30, 2020$1.15M+14.1%
FY2019Jun 30, 2019$1.01M+171.8%
FY2018Jun 30, 2018$370.85K-20.5%
FY2017Jun 30, 2017$466.35K+1130.5%
FY2016Jun 30, 2016$37.90K+803.3%
FY2015Jun 30, 2015$4.20K-91.5%
FY2014Jun 30, 2014$49.42K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026$3.58M+192.4%
Q3 FY2026CQ1 2026Mar 31, 2026$3.18M+136.2%
Q2 FY2026CQ4 2025Dec 31, 2025$4.27M-9.3%
Q1 FY2026CQ3 2025Sep 30, 2025$2.94M+47.5%
Q4 FY2025CQ2 2025Jun 30, 2025$1.22M-40.4%
Q3 FY2025CQ1 2025Mar 31, 2025$1.34M-76.4%
Q2 FY2025CQ4 2024Dec 31, 2024$4.70M-27.3%
Q1 FY2025CQ3 2024Sep 30, 2024$1.99M-77.6%
Q4 FY2024CQ2 2024Jun 30, 2024$2.05M-75.3%
Q3 FY2024CQ1 2024Mar 31, 2024$5.70M-49.1%
Q2 FY2024CQ4 2023Dec 31, 2023$6.47M-8.0%
Q1 FY2024CQ3 2023Sep 30, 2023$8.88M+31.1%
Q4 FY2023CQ2 2023Jun 30, 2023$8.30M+41.3%
Q3 FY2023CQ1 2023Mar 31, 2023$11.20M+213.0%
Q2 FY2023CQ4 2022Dec 31, 2022$7.03M+49.2%
Q1 FY2023CQ3 2022Sep 30, 2022$6.77M+118.8%
Q4 FY2022CQ2 2022Jun 30, 2022$5.87M+1018.4%
Q3 FY2022CQ1 2022Mar 31, 2022$3.58M+353.0%
Q2 FY2022CQ4 2021Dec 31, 2021$4.71M+402.5%
Q1 FY2022CQ3 2021Sep 30, 2021$3.09M+2966.7%
Q4 FY2021CQ2 2021Jun 30, 2021$525.09K+256.1%
Q3 FY2021CQ1 2021Mar 31, 2021$789.58K+123.6%
Q2 FY2021CQ4 2020Dec 31, 2020$938.10K+170.7%
Q1 FY2021CQ3 2020Sep 30, 2020$100.91K-70.4%
Q4 FY2020CQ2 2020Jun 30, 2020$147.46K-46.5%
Q3 FY2020CQ1 2020Mar 31, 2020$353.20K-11.8%
Q2 FY2020CQ4 2019Dec 31, 2019$346.51K+261.9%
Q1 FY2020CQ3 2019Sep 30, 2019$341.50K+635.7%
Q4 FY2019CQ2 2019Jun 30, 2019$275.73K+47.6%
Q1 FY2019CQ3 2018Dec 31, 2018$400.54K+857.0%
Q4 FY2018CQ2 2018Jun 30, 2018$95.74K+5.8%
Q3 FY2018CQ1 2018Mar 31, 2018$46.42K-61.3%
Q2 FY2018CQ4 2017Dec 31, 2017$186.84K+45.3%
Q1 FY2018CQ3 2017Sep 30, 2017$41.85K-67.1%
Q4 FY2017CQ2 2017Jun 30, 2017$90.48K–
Q3 FY2017CQ1 2017Mar 31, 2017$120.04K–
Q2 FY2017CQ4 2016Dec 31, 2016$128.56K–
Q1 FY2017CQ3 2016Sep 30, 2016$127.27K–

More BioVie figures

See a number that looks wrong?